ClearPoint Neuro, Inc.

ClearPoint Neuro develops and commercializes platforms for minimally invasive neurosurgical procedures guided by magnetic resonance imaging. The company's primary product, the ClearPoint system, is an integrated platform that enables surgeons to insert deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as deliver pharmaceutical infusions directly into the brain tissue. The system addresses applications in movement disorders, epilepsy, pain management, and oncology.

The company maintains a network of collaborative relationships with medical device manufacturers, pharmaceutical companies, and academic institutions, including agreements with Philips for imaging integration, UCB Biopharma for drug delivery applications, and research partnerships with the University of California, San Francisco and Johns Hopkins University. These partnerships support both technological development and clinical validation across multiple therapeutic areas.

ClearPoint Neuro operates primarily within the United States market with a workforce of approximately 115 full-time employees. The company is incorporated in Delaware and maintains headquarters in Solana Beach, California. It was formerly known as MRI Interventions, Inc. until its name change in February 2020, reflecting the evolution of its technology platform and clinical focus.